This application describes a four stage program to develop an Anthrax rPA vaccine with a significantly improved stability. An output from this program would be a vaccine candidate that when successfully licensed does not require refrigerated storage or supply chain, providing the government with a stockpile that is less costly to maintain and deploy. The vaccine would be more robust in terms of it ability to withstand temperature extremes simplifying use in the field. The program also examines formulations that do not contain alhyrdrogel potentially yielding a safer product. The program studies lyophilisation, micro-encapsulation, micro-particle crystallisation and glassification in four stages designed to progress only those technologies showing a measurable improvement in stability without compromising potency in an animal challenge test and immunological response using surrogate markers. In stage 1 initial process development and optimisation will be carried out using all technologies to produce formulations usuable for accelerated stability trials in stage 2 and extensive previously developed Drug substance and Drug Product characterisation tests and assays will be used to examine the effect of the technologies on the vaccine. In Stage 3 will develop one technology process to GMP pilot plant manufacture to produce material that will be used in stage 4 for toxicity. This data will then be used to design, cost and plan a non-clinical and clinical program to achieve license. Relevance This program targets the development of an anthrax vaccine with improved stability over currently available products. The successful completion of the program would yield an anthrax vaccine candidate that when licensed would reduce the costs of maintaining a National Stockpile. In addition, improved stability and robustness in use would greatly simplify the logistics for deploying the vaccine in a emergency yielding greater protection to the public.
| Watkinson, Allan; Soliakov, Andrei; Ganesan, Ashok et al. (2013) Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions. Clin Vaccine Immunol 20:1659-68 |
| Soliakov, Andrei; Kelly, Ian F; Lakey, Jeremy H et al. (2012) Anthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®. Eur J Pharm Biopharm 80:25-32 |
| Ganesan, Ashok; Watkinson, Allan; Moore, Barry D (2012) Biophysical characterisation of thermal-induced precipitates of recombinant anthrax protective antigen: evidence for kinetically trapped unfolding domains in solid-state. Eur J Pharm Biopharm 82:475-84 |
